Ozempic Maker Novo Nordisk Plans Bond Sale to Fund Expansion
- Drugmaker mandates international banks for investor calls
- Novo is investing to expand production of weight-loss drugs
This article is for subscribers only.
Novo Nordisk A/S plans to sell bonds for the first time in more than two years to help finance its large program to expand production of its blockbuster treatments.
Novo would be testing the bond market for the first time since it became Europe’s most valuable company and a pop-culture phenomenon, sparked by excessive demand for its diabetes drug Ozempic and obesity treatment Wegovy.